Abstract 2789
Background
The Catalan Institute of Oncology (ICO) is a specialised cancer institution. It has four centres distributed around Catalonia that covers 45% of the adult cancer patient population in the autonomy. In three of them exists a radiotherapy department: L’Hospitalet, Badalona and Girona; with 11 accelerators altogether. Near 6.000 patients per year receive treatment in them. All radiotherapy departments in Spain need to accomplish with a quality system. ICO has a system based in International Organization for Standardization (ISO) regulations. Recently, a new system of ISO certification (ISO 9001:2015) has required increasing the homogenization level among our three departments. In addition, ICO promotes equality in access to services and assistance. For all these reasons it was developed the “Standardize project of the assistance procedures in Oncologic radiation”.
Methods
The ISO whole process was divided in 6 sub processes. In each center there was a group of professionals who works with every sub process and discuss with the other hospitals in order to define the common procedures. In February 2018, we started a work plan to do it through teleconference meetings. Nurses and radiotherapist technicians were included and nominate several leaders in each of the working groups which involved their activity. Meeting works ended in June 2018. From then until 2019 July we run with the implementation time.
Results
Nurses and radiotherapist technicians of the three institutions defined the list of agreements and consensus to do: homogeneous written education for patients to implement the active identification with patients Image guided radiotherapy protocols (IGRT) protocols for management break on treatments & short interruptions safety check list for the first session patient follow-up, alternating nurses and physicians nurse appointment at the end of treatments quality indicators for activity & schedules.
Conclusions
This project has assured that population from 3 different areas will receive same treatments, under equal circumstances. We incorporated strengths of each centre, using now a unique map of the process of radiotherapy. Furthermore we share same safety and prevention standards and a prospective system for risk analysis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institut Català d’Oncologia.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3524 - Cabazitaxel For Octogenarian Patients With Metastatic Castration-Resistant Prostate Cancer (MCRPC).
Presenter: Paolo Tralongo
Session: Poster Display session 3
Resources:
Abstract
5637 - External Validation of a Prognostic Score in First-Line Metastastic Castration-Resistant Prostate Cancer (mCRPC)
Presenter: David Lorente
Session: Poster Display session 3
Resources:
Abstract
3228 - Treatment outcomes of 3rd treatment in a real-world metastatic castration resistant prostate cancer (mCRPC) population: results from the Dutch CAPRI-registry
Presenter: Jessica Notohardjo
Session: Poster Display session 3
Resources:
Abstract
4695 - Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion>5%: a propensity score matching analysis from SEER database
Presenter: Junru Chen
Session: Poster Display session 3
Resources:
Abstract
4438 - Multi-institutional evaluation of therapeutic management for oligometastatic cancer prostate recurrence with choline-PET/CT
Presenter: Morgane Guibert-broudic
Session: Poster Display session 3
Resources:
Abstract
4574 - Safety of new androgen receptor inhibitors (ARi) in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): a network meta-analysis of randomized controlled trials (RCT)
Presenter: Amelia Altavilla
Session: Poster Display session 3
Resources:
Abstract
3816 - Real-world use of radium-223 for treatment of metastatic castration resistant-prostate cancer (mCRPC): results from the Dutch CAPRI registry
Presenter: Malou Kuppen
Session: Poster Display session 3
Resources:
Abstract
5180 - A phase 2a study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Daniel Petrylak
Session: Poster Display session 3
Resources:
Abstract
1067 - Adding ADT to PSMA-PET/CT-guided SBRT for oligometastatic prostate cancer improves distant progression-free survival
Presenter: Carole Mercier
Session: Poster Display session 3
Resources:
Abstract
5529 - Safety and efficacy of Ac-225-PSMA-617 in metastatic castration resistant prostate cancer (mCRPC) after failure of Lu-177-PSMA
Presenter: Robert Tauber
Session: Poster Display session 3
Resources:
Abstract